Home World News EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab World News EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... December 20, 2018 EMA Recommends Granting a Marketing Authorisation for Ensartinib October 9, 2026 Reunión anual de la American Society of Clinical Oncology de 2023:... June 6, 2023 Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher... February 9, 2021 Load more HOT NEWS Real-World Patients with Cancer Show Lower Survival Times and Treatment-Associated Survival... Can AI Help Predict Which Cancer Patients Should Be Treated with... FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in...
